Sosei Group Corporation

75 articles with Sosei Group Corporation

• Sosei Group Corporation Announces Private Placement of New Shares by its Subsidiary

  3/8/2012

• Sosei Group Corporation Announces Initiation of Phase I Study for SO-1105

  3/8/2012

• Sosei Group Corporation Release: NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress

  9/27/2011

• Sosei Group Corporation to Receive Grant from NEDO's FY2011 Innovation Promotion Programme for Development of Innovative Ophthalmic Solutions

  8/23/2011

• Sosei Group Corporation to Acquire Activus Pharma

  6/21/2010

• Sosei Group Corporation Signs Definitive Distribution Agreement With ASKA Pharmaceutical for Commercialization of SOH-075

  11/2/2009

• Sosei Group Corporation Announces Deal With UK Biotech Company

  10/14/2009

• Sosei Group Corporation Assigns AD 923 Assets to Pharmasol

  10/6/2009

• Sosei Group Corporation Announces Filing of NDA for SOH-075 (NorLevo(R)) in Japan

  9/30/2009

• Sosei Group Corporation: QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting

  9/16/2009

• Sosei Group Corporation and Vectura Group plc Announce Start of Phase III Clinical Study With NVA237

  6/29/2009

• Sosei Group Corporation Announces Buyback of the Commercialization Rights to AD 923 from Mundipharma AG

  12/29/2008

• Sosei Group Corporation Confirms the Safety of SD118 in Two Phase I Trials

  12/8/2008

• Sosei Group Corporation Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria

  11/26/2008

• Sosei Group Corporation and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting

  11/19/2008